about
Valproate in the treatment of epilepsy in girls and women of childbearing potentialTreatment of myoclonusCoagulation abnormalities and acquired von Willebrand's disease type 1 in children receiving valproic acid.Valproate-associated coagulopathies in children during short-term treatment.Thrombocytopenia secondary to high valproate levels in children with epilepsy.A prospective study between carbamazepine, phenytoin and sodium valproate as monotherapy in previously untreated and recently diagnosed patients with epilepsyComplex partial seizures: EEG foci and response to carbamazepine and sodium valproateRational approach to treatment options for Lennox-Gastaut syndrome.An update on sodium valproate.Visual sensitivity and epilepsy: a proposed terminology and classification for clinical and EEG phenomenology.Choosing antiepileptic drugs for developmentally normal children with specific epilepsy syndromes and behavioral disorders.Idiopathic generalized epilepsies: clinical and electroencephalogram diagnosis and treatment.The treatment of juvenile myoclonic epilepsy.Extended-release formulations in epilepsy.Weight gain in children treated with valproate.Managing severe epilepsy syndromes of early childhood.Sex-specific differences in side effects of psychotropic drugs: genes or gender?Treatment of epilepsies associated with typical absences.Epilepsy, sex hormones and antiepileptic drugs in female patients.Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications.Pharmacotherapy for children and adolescents with epilepsy.Management of seizures in Lennox-Gastaut syndrome.Treatment of idiopathic generalized epilepsy - a review of the evidence.Valproic acid for the treatment of malignant gliomas: review of the preclinical rationale and published clinical results.Treatment of myoclonic seizures.Treating myoclonic epilepsy in children: state-of-the-art.Current and emerging treatments for absence seizures in young patientsThe efficacy and tolerability of pharmacologic treatment options for Lennox-Gastaut syndrome.Modern management of juvenile myoclonic epilepsy.Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy.Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats.[Acute hepatic failure associated with valproic acid in children. Report of 3 cases]Advances in pharmacotherapy: recent developments in the treatment of epilepsy.Effect of sodium valproate on carbamazepine disposition and psychomotor profile in man.Olanzapine-induced diabetes mellitus.Inhibition by carbapenem antibiotic imipenem of intestinal absorption of valproic acid in rats.Myoclonic status epilepticus: video presentation.Insulin resistance in epileptic girls who gain weight after therapy with valproic acid.Epileptic seizures in general practice.Topiramate for the treatment of juvenile myoclonic epilepsy.
P2860
Q26865670-95AF2B56-2203-4678-819B-95A1F098EF87Q27025673-E98ABDA4-F46E-4605-B76E-EA2C5F1F5229Q33341608-864C0828-48FC-4EBD-A4D9-3D2251FDD47AQ33384723-32CCE8FA-A233-49A6-994C-3F7C09FABA63Q33490952-A4816847-952B-45D6-8781-9A80DF213981Q33621179-06C2D9FD-EA53-49C4-B26D-8EA63A0F8131Q33621533-C483641B-9DB1-4584-9FFD-F567756447A7Q33971818-6E03011F-2E50-4D08-8897-FECA46C445C6Q34195505-EF284447-BBF8-4EB2-A36A-85EAE25577C6Q34266373-586B60D3-7921-4D42-BAF9-A597A9D94B27Q35939596-3A32F3F5-823A-4E19-AEA3-BEE2DFA05773Q36307856-54C600FB-9FF1-464C-9D41-7F32A216B9D8Q36511305-39B2A323-F8B3-4955-8C4B-62ABA98FB73AQ36875598-1BA220A9-B853-4C5A-9F84-81AED7FD290EQ37405705-C3A07FFA-CE02-4D23-80C1-980441F4A002Q37576853-569F8790-439F-4000-A024-619921292D75Q37598900-C5109CDD-4953-4845-9AB9-B1C336D40A6DQ37610185-FE75D753-E9CF-4DAF-9725-5954CAF0388FQ37642006-65726CC7-1E50-4C67-B571-37EB5B0544ABQ37794213-55F5457A-0873-41F7-B0DF-35DE07372C9BQ37826193-562B476A-F344-4809-9A0C-9D8D99BC7E65Q37847141-2C796981-39AB-4638-93EE-F4F750A62974Q38008462-4DEDC38E-5BCC-484B-8583-DC1C85269431Q38016227-7E4E7F37-AD9D-4CCF-97F3-4EC09BD86A66Q38067140-F8A35CF5-1E67-43B1-990F-8AF6BC43A206Q38106487-8D7DE05A-3305-4F88-BEF2-3649FCE82F07Q38124030-6513DD70-CD24-4FBC-808F-712A0AB38A64Q38256868-7B438F18-8BD1-49C2-875D-89B16192D08BQ38809047-367EE3A0-B13E-4DC7-A5CF-7BCB3AF5D3D9Q38856766-C3CA8AFF-48C8-4EAF-8FCF-88D5B2291B46Q39559624-F19CFFD6-D273-4948-9959-3354731A506CQ40660090-2043C53A-B499-483F-ADC9-329EEEEF7D52Q40774655-627528A6-957D-4574-9488-129E40FA9072Q43229323-B2E0AEE3-BCC1-4044-ACB4-E719357AFDA3Q43602823-C84D9107-7DAB-4BCB-856A-59F0036CFFA5Q43655077-681F81D0-6DFE-4DA5-9D94-2002D2CF5A7DQ43938534-2E70321B-A1AB-456D-BC48-52337A384E52Q44043948-D324D5D0-5EB9-4F22-951C-E526FEFEC67CQ46434583-20B4273B-5EB2-4301-B761-BE13DC06C95BQ46782318-5B0EA092-E5C5-45F4-ACE1-723B66E93FF1
P2860
description
1982 nî lūn-bûn
@nan
1982年の論文
@ja
1982年論文
@yue
1982年論文
@zh-hant
1982年論文
@zh-hk
1982年論文
@zh-mo
1982年論文
@zh-tw
1982年论文
@wuu
1982年论文
@zh
1982年论文
@zh-cn
name
Sodium valproate: monotherapy and polytherapy.
@en
Sodium valproate: monotherapy and polytherapy.
@nl
type
label
Sodium valproate: monotherapy and polytherapy.
@en
Sodium valproate: monotherapy and polytherapy.
@nl
prefLabel
Sodium valproate: monotherapy and polytherapy.
@en
Sodium valproate: monotherapy and polytherapy.
@nl
P2093
P2860
P1433
P1476
Sodium valproate: monotherapy and polytherapy.
@en
P2093
P2860
P304
P356
10.1111/J.1528-1157.1982.TB05085.X
P577
1982-12-01T00:00:00Z